Glutathione / ROS Cancer Research Results

Natural Products Affecting GSH
Compound	        Effect
Curcumin	        ↓ GSH in cancer cells
Sulforaphane	        Transient NRF2 activation → later depletion
Resveratrol	        Disrupts GSH recycling
Quercetin	        Consumes GSH during detox
Selenium compounds	Dose-dependent: support GPX or induce redox stress
High-dose Vitamin C	Depletes GSH via ROS overload

Glutathione — an endogenous sulfur-containing tripeptide composed of glutamate, cysteine, and glycine and the principal low-molecular-weight intracellular thiol antioxidant. Reduced glutathione is abbreviated GSH; its oxidized disulfide form is GSSG, and the GSH/GSSG ratio is a major indicator of cellular redox status. Glutathione functions as a cofactor for glutathione peroxidases, participates in electrophile and drug conjugation through glutathione S-transferases, maintains protein thiol redox state, and supports mitochondrial redox homeostasis. In cancer, glutathione has a strongly context-dependent and frequently tumor-protective role: many tumors increase GSH synthesis, recycling, or utilization to tolerate oxidative stress and resist chemotherapy, radiotherapy, and ferroptosis. Consequently, therapeutic cancer research more often targets GSH depletion or the upstream system xc−/GCLC/GSH/GPX4 axis than administers GSH as an anticancer agent.

Primary mechanisms (ranked):

1. Intracellular redox buffering through the GSH/GSSG couple and glutathione-peroxidase-dependent detoxification of hydrogen peroxide and organic peroxides.
2. Suppression of ferroptosis through the GSH-dependent activity of GPX4, which reduces membrane phospholipid hydroperoxides.
3. Detoxification of electrophilic xenobiotics and anticancer drugs through glutathione S-transferase-mediated conjugation, contributing to treatment resistance in some cancers.
4. Maintenance of mitochondrial redox homeostasis and protection against mitochondrial permeability transition, oxidative injury, and apoptosis.
5. Protein S-glutathionylation and deglutathionylation, which regulate redox-sensitive signaling, protein activity, stress responses, proliferation, and cell-death pathways.
6. NRF2-regulated glutathione synthesis and recycling is an important upstream control system; persistent NRF2 activation in some tumors increases GSH-dependent antioxidant capacity and treatment resistance.

Bioavailability / PK relevance: Oral glutathione is partially degraded in the gastrointestinal tract, but controlled human studies demonstrate that sustained oral dosing can increase blood and cellular glutathione stores. A 6-month randomized trial using 250 or 1,000 mg/day increased GSH in several blood compartments, indicating that oral bioavailability is not negligible. The magnitude of tissue exposure is nevertheless formulation-, dose-, duration-, and tissue-dependent. Direct delivery of intact GSH into tumors or the brain is substantially less predictable than changes in peripheral glutathione status.

In-vitro vs systemic exposure relevance: Many mechanistic cancer experiments manipulate intracellular GSH genetically or pharmacologically rather than reproducing concentrations achievable through oral supplementation. Extracellular millimolar GSH concentrations sometimes used experimentally should therefore not be interpreted as equivalent to oral supplementation. The biologically relevant variable in cancer is generally intracellular GSH synthesis, recycling, compartmentalization, and GPX4 availability rather than plasma GSH alone.

Clinical evidence status: Glutathione is not an established anticancer treatment. Human oncology evidence is primarily adjunctive, including older trials of intravenous reduced glutathione intended to reduce platinum-associated neurotoxicity or other chemotherapy toxicity; some studies reported neuroprotection without obvious loss of tumor response, but this does not establish anticancer efficacy. A contemporary trial is investigating GSH with anti-PD-1-based therapy in non-small-cell lung cancer, so direct anticancer use remains investigational. In Canada, oral glutathione is available in licensed Natural Health Products with antioxidant-related claims, not cancer-treatment indications. Injectable compounded glutathione requires additional caution because sterility and endotoxin contamination can produce serious adverse events.

Glutathione Cancer-Relevant Mechanisms

Alzheimer’s disease relevance: Brain glutathione is mechanistically relevant to Alzheimer’s disease because GSH is a major neuronal and glial antioxidant and human magnetic-resonance spectroscopy studies have demonstrated reduced hippocampal GSH in mild cognitive impairment and Alzheimer’s disease, with lower levels associated with cognitive impairment. The therapeutic rationale is therefore restoration of deficient antioxidant capacity rather than suppression of GSH. However, direct oral or intravenous glutathione has not been established as a disease-modifying AD therapy, and evidence for specifically increasing brain GSH with standard oral GSH remains substantially weaker than evidence showing an association between endogenous brain GSH depletion and AD.

Clinical evidence status: Human evidence is primarily biomarker and observational evidence demonstrating brain GSH depletion, supported by mechanistic and preclinical studies. Direct glutathione supplementation lacks convincing randomized clinical evidence for cognitive or disease-modifying benefit in AD. Strategies using GSH precursors such as cysteine or N-acetylcysteine are related but should be treated separately from direct glutathione supplementation.

Glutathione Alzheimer’s-Relevant Mechanisms